MoonLake Immunotherapeutics (MLTX) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Join SI Premium – FREE
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q3 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).
For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MoonLake Immunotherapeutics (MLTX) Misses Q3 EPS by 15c
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Moonlake Immunotherapeutics (MLTX) PT Lowered to $16 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
